ReviewFrontiers in immunology2026
Lysosomal checkpoints in renal autoimmunity: from antigen processing to metabolic-immune crosstalk.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysosomes serve as critical intracellular hubs for degradation and signaling, playing a central role in maintaining immune homeostasis. In recent years, lysosomal functions have been conceptualized as a series of "checkpoints" that finely regulate the initiation and progression of autoimmune kidney diseases. This review systematically examines the multifaceted roles of lysosomal checkpoints in renal autoimmunity, with a focus on their mechanisms in autoantigen processing and presentation, immune cell activation and breakdown of tolerance, and the emerging area of metabolic-immune crosstalk. By integrating the latest research, this article aims to elucidate the potential of targeting lysosomal pathways as a novel therapeutic strategy for autoimmune kidney diseases such as lupus nephritis and ANCA-associated vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.